UK markets closed
  • NIKKEI 225

    27,728.12
    +144.04 (+0.52%)
     
  • HANG SENG

    26,204.69
    -221.86 (-0.84%)
     
  • CRUDE OIL

    69.06
    +0.91 (+1.34%)
     
  • GOLD FUTURES

    1,807.00
    -7.50 (-0.41%)
     
  • DOW

    34,996.10
    +203.43 (+0.58%)
     
  • BTC-GBP

    28,961.51
    +560.45 (+1.97%)
     
  • CMC Crypto 200

    997.19
    +21.29 (+2.18%)
     
  • ^IXIC

    14,876.38
    +95.85 (+0.65%)
     
  • ^FTAS

    4,089.91
    +4.44 (+0.11%)
     

Global Neuromodulation Market to Reach US$8.9 Billion by the Year 2027

·22-min read

Abstract: - Global Neuromodulation Market to Reach US$8. 9 Billion by the Year 2027. - Amid the COVID-19 crisis, the global market for Neuromodulation estimated at US$5.

New York, June 24, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Neuromodulation Industry" - https://www.reportlinker.com/p05957502/?utm_source=GNW
1 Billion in the year 2020, is projected to reach a revised size of US$8.9 Billion by 2027, growing at a CAGR of 8.2% over the analysis period 2020-2027.Spinal Cord Stimulation, one of the segments analyzed in the report, is projected to grow at a 8.3% CAGR to reach US$3.9 Billion by the end of the analysis period.After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Deep Brain Stimulation segment is readjusted to a revised 8.6% CAGR for the next 7-year period. This segment currently accounts for a 16.7% share of the global Neuromodulation market.

- The U.S. Accounts for Over 48.4% of Global Market Size in 2020, While China is Forecast to Grow at a 10% CAGR for the Period of 2020-2027

- The Neuromodulation market in the U.S. is estimated at US$2.5 Billion in the year 2020. The country currently accounts for a 48.43% share in the global market. China, the world second largest economy, is forecast to reach an estimated market size of US$663.5 Million in the year 2027 trailing a CAGR of 10% through 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 7.9% and 8.4% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 7.5% CAGR while Rest of European market (as defined in the study) will reach US$663.5 Million by the year 2027.

- Sacral Nerve Stimulation Segment Corners a 15.1% Share in 2020

- In the global Sacral Nerve Stimulation segment, USA, Canada, Japan, China and Europe will drive the 7.3% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$696.3 Million in the year 2020 will reach a projected size of US$1.1 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$528.2 Million by the year 2027.

- Select Competitors (Total 83 Featured)

  • Abbott Laboratories

  • Aleva Neurotherapeutics SA

  • Bioness Inc.

  • Boston Scientific Corporation

  • EnteroMedics, Inc.

  • LivaNova PLC

  • Medtronic PLC

  • NeuroPace, Inc.

  • Nevro Corp.




Read the full report: https://www.reportlinker.com/p05957502/?utm_source=GNW

CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Neurological Disorders
A Prelude to Neuromodulation
Indications for Neuromodulation Therapy
Impact of Covid-19 and a Looming Global Recession
2020 Marked as a Year of Disruption & Transformation
EXHIBIT 1: World Economic Growth Projections (Real GDP, Annual
% Change) for 2020 through 2022
Global Neuromodulation Market Buckles under COVID-19 Strain
Effects of COVID-19 on the Nervous System Sheds Focus on
Neuromodulation Applications
GLOBAL MARKET OVERVIEW
Neuromodulation Market Set for a Robust Growth
Neuromodulation Market by Segment
Spinal Cord Stimulation (SCS) and Deep Brain Stimulation (DBS)
Represents the Largest Segments
Neuromodulation Devices by Technology
EXHIBIT 2: Spinal Cord Stimulation Market (2020): Dollar Market
Share of Leading Players in Percentage
Neuromodulation Market by Application
Growing Clinical Applications to Drive Demand
US and Europe Dominate the Market
Asia-Pacific and other Emerging Regions Display Impressive
Growth Potential
Competition
Select FDA Approved Neuromodulation Devices in Recent Years
Recent Market Activity
Market Restraints and Challenges
WORLD BRANDS

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS
High Incidence of Neurological Disorders: A Key Market Driver
EXHIBIT 3: Annual Incidence of Adult-Onset Neurologic Disorders
in the US
Rising Geriatric Population and Subsequent Growth in Prevalence
of Neurological Disorders
EXHIBIT 4: Global Population Statistics for the 65+ Age Group
in Million by Geographic Region for the Years 2019, 2025, 2035
and 2050
Growing Incidence of Neurodegenerative Diseases Propels the
Market for Deep Brain Stimulation Devices
EXHIBIT 5: Global Alzheimer’s Prevalence by Age Group
EXHIBIT 6: Diagnosed Prevalence Cases of Parkinson?s Disease
Across Select Countries
EXHIBIT 7: Global DBS Market by Leading Player (2020E): Market
Share Breakdown of Revenues for Medtronic, Boston Scientific,
and Abbott
Select Available Deep Brain Stimulation Devices Available in
the Market
Increasing Cases of Epilepsy Drives the Demand for Vagus Nerve
Stimulation Devices
EXHIBIT 8: Epilepsy Incidence by Type (2019): Percentage Share
Breakdown for Idiopathic and Symptomatic Epilepsy
EXHIBIT 9: Symptomatic Epilepsy Incidence by Type (2019):
Percentage Share Breakdown of Congenital, Degenerative,
Infective, Neoplastic, Trauma, and Vascular Epilepsy
Spinal Cord Injuries Propel the Demand for Spinal Cord
Stimulation Devices
Recent Developments in Spinal Cord Injury Treatment
TENS (Transcutaneous electrical nerve stimulation devices)
Market Witnesses Rapid Growth
Non-Invasiveness of TMS (Transcranial Magnetic Stimulation)
Propelling the adoption of TMS devices
Neuromodulation Technologies to Gain Preference Over Opioids
Tibial Neuromodulation to Impact Overactive Bladder Market

4. GLOBAL MARKET PERSPECTIVE
Table 1: World Current & Future Analysis for Neuromodulation by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2020 through 2027 and
% CAGR

Table 2: World Historic Review for Neuromodulation by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 3: World 15-Year Perspective for Neuromodulation by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World Markets for Years 2012, 2020 & 2027

Table 4: World Current & Future Analysis for Spinal Cord
Stimulation by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2020 through
2027 and % CAGR

Table 5: World Historic Review for Spinal Cord Stimulation by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 6: World 15-Year Perspective for Spinal Cord Stimulation
by Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

Table 7: World Current & Future Analysis for Deep Brain
Stimulation by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2020 through
2027 and % CAGR

Table 8: World Historic Review for Deep Brain Stimulation by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 9: World 15-Year Perspective for Deep Brain Stimulation
by Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

Table 10: World Current & Future Analysis for Sacral Nerve
Stimulation by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2020 through
2027 and % CAGR

Table 11: World Historic Review for Sacral Nerve Stimulation by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 12: World 15-Year Perspective for Sacral Nerve
Stimulation by Geographic Region - Percentage Breakdown of
Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific
and Rest of World for Years 2012, 2020 & 2027

Table 13: World Current & Future Analysis for Vagus Nerve
Stimulation by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2020 through
2027 and % CAGR

Table 14: World Historic Review for Vagus Nerve Stimulation by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 15: World 15-Year Perspective for Vagus Nerve Stimulation
by Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

Table 16: World Current & Future Analysis for Transcutaneous
Electrical Nerve Stimulation by Geographic Region - USA,
Canada, Japan, China, Europe, Asia-Pacific and Rest of World
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2020 through 2027 and % CAGR

Table 17: World Historic Review for Transcutaneous Electrical
Nerve Stimulation by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 18: World 15-Year Perspective for Transcutaneous
Electrical Nerve Stimulation by Geographic Region - Percentage
Breakdown of Value Sales for USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

Table 19: World Current & Future Analysis for Repetitive
Transcranial Magnetic Stimulation by Geographic Region - USA,
Canada, Japan, China, Europe, Asia-Pacific and Rest of World
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2020 through 2027 and % CAGR

Table 20: World Historic Review for Repetitive Transcranial
Magnetic Stimulation by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 21: World 15-Year Perspective for Repetitive Transcranial
Magnetic Stimulation by Geographic Region - Percentage
Breakdown of Value Sales for USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

Table 22: World Current & Future Analysis for Other
Technologies by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2020 through
2027 and % CAGR

Table 23: World Historic Review for Other Technologies by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 24: World 15-Year Perspective for Other Technologies by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

Table 25: World Current & Future Analysis for Chronic Pain by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2020 through 2027 and
% CAGR

Table 26: World Historic Review for Chronic Pain by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Thousand for Years 2012 through 2019 and % CAGR

Table 27: World 15-Year Perspective for Chronic Pain by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

Table 28: World Current & Future Analysis for Failed Back
Syndrome by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2020 through
2027 and % CAGR

Table 29: World Historic Review for Failed Back Syndrome by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 30: World 15-Year Perspective for Failed Back Syndrome by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

Table 31: World Current & Future Analysis for Depression by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2020 through 2027 and
% CAGR

Table 32: World Historic Review for Depression by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Thousand for Years 2012 through 2019 and % CAGR

Table 33: World 15-Year Perspective for Depression by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

Table 34: World Current & Future Analysis for Epilepsy by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2020 through 2027 and
% CAGR

Table 35: World Historic Review for Epilepsy by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Thousand for Years 2012 through 2019 and % CAGR

Table 36: World 15-Year Perspective for Epilepsy by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World for Years
2012, 2020 & 2027

Table 37: World Current & Future Analysis for Parkinson`s
Disease by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2020 through
2027 and % CAGR

Table 38: World Historic Review for Parkinson`s Disease by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 39: World 15-Year Perspective for Parkinson`s Disease by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

Table 40: World Current & Future Analysis for Migraine by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2020 through 2027 and
% CAGR

Table 41: World Historic Review for Migraine by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Thousand for Years 2012 through 2019 and % CAGR

Table 42: World 15-Year Perspective for Migraine by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World for Years
2012, 2020 & 2027

Table 43: World Current & Future Analysis for Other
Applications by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2020 through
2027 and % CAGR

Table 44: World Historic Review for Other Applications by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 45: World 15-Year Perspective for Other Applications by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

UNITED STATES
Table 46: USA Current & Future Analysis for Neuromodulation by
Technology - Spinal Cord Stimulation, Deep Brain Stimulation,
Sacral Nerve Stimulation, Vagus Nerve Stimulation,
Transcutaneous Electrical Nerve Stimulation, Repetitive
Transcranial Magnetic Stimulation and Other Technologies -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 47: USA Historic Review for Neuromodulation by Technology -
Spinal Cord Stimulation, Deep Brain Stimulation, Sacral Nerve
Stimulation, Vagus Nerve Stimulation, Transcutaneous Electrical
Nerve Stimulation, Repetitive Transcranial Magnetic Stimulation
and Other Technologies Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 48: USA 15-Year Perspective for Neuromodulation by
Technology - Percentage Breakdown of Value Sales for Spinal
Cord Stimulation, Deep Brain Stimulation, Sacral Nerve
Stimulation, Vagus Nerve Stimulation, Transcutaneous Electrical
Nerve Stimulation, Repetitive Transcranial Magnetic Stimulation
and Other Technologies for the Years 2012, 2020 & 2027

Table 49: USA Current & Future Analysis for Neuromodulation by
Application - Chronic Pain, Failed Back Syndrome, Depression,
Epilepsy, Parkinson`s Disease, Migraine and Other Applications -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 50: USA Historic Review for Neuromodulation by
Application - Chronic Pain, Failed Back Syndrome, Depression,
Epilepsy, Parkinson`s Disease, Migraine and Other Applications
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR

Table 51: USA 15-Year Perspective for Neuromodulation by
Application - Percentage Breakdown of Value Sales for Chronic
Pain, Failed Back Syndrome, Depression, Epilepsy, Parkinson`s
Disease, Migraine and Other Applications for the Years 2012,
2020 & 2027

CANADA
Table 52: Canada Current & Future Analysis for Neuromodulation
by Technology - Spinal Cord Stimulation, Deep Brain
Stimulation, Sacral Nerve Stimulation, Vagus Nerve Stimulation,
Transcutaneous Electrical Nerve Stimulation, Repetitive
Transcranial Magnetic Stimulation and Other Technologies -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 53: Canada Historic Review for Neuromodulation by
Technology - Spinal Cord Stimulation, Deep Brain Stimulation,
Sacral Nerve Stimulation, Vagus Nerve Stimulation,
Transcutaneous Electrical Nerve Stimulation, Repetitive
Transcranial Magnetic Stimulation and Other Technologies
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR

Table 54: Canada 15-Year Perspective for Neuromodulation by
Technology - Percentage Breakdown of Value Sales for Spinal
Cord Stimulation, Deep Brain Stimulation, Sacral Nerve
Stimulation, Vagus Nerve Stimulation, Transcutaneous Electrical
Nerve Stimulation, Repetitive Transcranial Magnetic Stimulation
and Other Technologies for the Years 2012, 2020 & 2027

Table 55: Canada Current & Future Analysis for Neuromodulation
by Application - Chronic Pain, Failed Back Syndrome,
Depression, Epilepsy, Parkinson`s Disease, Migraine and Other
Applications - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 56: Canada Historic Review for Neuromodulation by
Application - Chronic Pain, Failed Back Syndrome, Depression,
Epilepsy, Parkinson`s Disease, Migraine and Other Applications
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR

Table 57: Canada 15-Year Perspective for Neuromodulation by
Application - Percentage Breakdown of Value Sales for Chronic
Pain, Failed Back Syndrome, Depression, Epilepsy, Parkinson`s
Disease, Migraine and Other Applications for the Years 2012,
2020 & 2027

JAPAN
Table 58: Japan Current & Future Analysis for Neuromodulation
by Technology - Spinal Cord Stimulation, Deep Brain
Stimulation, Sacral Nerve Stimulation, Vagus Nerve Stimulation,
Transcutaneous Electrical Nerve Stimulation, Repetitive
Transcranial Magnetic Stimulation and Other Technologies -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 59: Japan Historic Review for Neuromodulation by
Technology - Spinal Cord Stimulation, Deep Brain Stimulation,
Sacral Nerve Stimulation, Vagus Nerve Stimulation,
Transcutaneous Electrical Nerve Stimulation, Repetitive
Transcranial Magnetic Stimulation and Other Technologies
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR

Table 60: Japan 15-Year Perspective for Neuromodulation by
Technology - Percentage Breakdown of Value Sales for Spinal
Cord Stimulation, Deep Brain Stimulation, Sacral Nerve
Stimulation, Vagus Nerve Stimulation, Transcutaneous Electrical
Nerve Stimulation, Repetitive Transcranial Magnetic Stimulation
and Other Technologies for the Years 2012, 2020 & 2027

Table 61: Japan Current & Future Analysis for Neuromodulation
by Application - Chronic Pain, Failed Back Syndrome,
Depression, Epilepsy, Parkinson`s Disease, Migraine and Other
Applications - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 62: Japan Historic Review for Neuromodulation by
Application - Chronic Pain, Failed Back Syndrome, Depression,
Epilepsy, Parkinson`s Disease, Migraine and Other Applications
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR

Table 63: Japan 15-Year Perspective for Neuromodulation by
Application - Percentage Breakdown of Value Sales for Chronic
Pain, Failed Back Syndrome, Depression, Epilepsy, Parkinson`s
Disease, Migraine and Other Applications for the Years 2012,
2020 & 2027

CHINA
Table 64: China Current & Future Analysis for Neuromodulation
by Technology - Spinal Cord Stimulation, Deep Brain
Stimulation, Sacral Nerve Stimulation, Vagus Nerve Stimulation,
Transcutaneous Electrical Nerve Stimulation, Repetitive
Transcranial Magnetic Stimulation and Other Technologies -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 65: China Historic Review for Neuromodulation by
Technology - Spinal Cord Stimulation, Deep Brain Stimulation,
Sacral Nerve Stimulation, Vagus Nerve Stimulation,
Transcutaneous Electrical Nerve Stimulation, Repetitive
Transcranial Magnetic Stimulation and Other Technologies
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR

Table 66: China 15-Year Perspective for Neuromodulation by
Technology - Percentage Breakdown of Value Sales for Spinal
Cord Stimulation, Deep Brain Stimulation, Sacral Nerve
Stimulation, Vagus Nerve Stimulation, Transcutaneous Electrical
Nerve Stimulation, Repetitive Transcranial Magnetic Stimulation
and Other Technologies for the Years 2012, 2020 & 2027

Table 67: China Current & Future Analysis for Neuromodulation
by Application - Chronic Pain, Failed Back Syndrome,
Depression, Epilepsy, Parkinson`s Disease, Migraine and Other
Applications - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 68: China Historic Review for Neuromodulation by
Application - Chronic Pain, Failed Back Syndrome, Depression,
Epilepsy, Parkinson`s Disease, Migraine and Other Applications
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR

Table 69: China 15-Year Perspective for Neuromodulation by
Application - Percentage Breakdown of Value Sales for Chronic
Pain, Failed Back Syndrome, Depression, Epilepsy, Parkinson`s
Disease, Migraine and Other Applications for the Years 2012,
2020 & 2027

EUROPE
Table 70: Europe Current & Future Analysis for Neuromodulation
by Geographic Region - France, Germany, Italy, UK and Rest of
Europe Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2020 through 2027 and % CAGR

Table 71: Europe Historic Review for Neuromodulation by
Geographic Region - France, Germany, Italy, UK and Rest of
Europe Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2012 through 2019 and % CAGR

Table 72: Europe 15-Year Perspective for Neuromodulation by
Geographic Region - Percentage Breakdown of Value Sales for
France, Germany, Italy, UK and Rest of Europe Markets for Years
2012, 2020 & 2027

Table 73: Europe Current & Future Analysis for Neuromodulation
by Technology - Spinal Cord Stimulation, Deep Brain
Stimulation, Sacral Nerve Stimulation, Vagus Nerve Stimulation,
Transcutaneous Electrical Nerve Stimulation, Repetitive
Transcranial Magnetic Stimulation and Other Technologies -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 74: Europe Historic Review for Neuromodulation by
Technology - Spinal Cord Stimulation, Deep Brain Stimulation,
Sacral Nerve Stimulation, Vagus Nerve Stimulation,
Transcutaneous Electrical Nerve Stimulation, Repetitive
Transcranial Magnetic Stimulation and Other Technologies
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR

Table 75: Europe 15-Year Perspective for Neuromodulation by
Technology - Percentage Breakdown of Value Sales for Spinal
Cord Stimulation, Deep Brain Stimulation, Sacral Nerve
Stimulation, Vagus Nerve Stimulation, Transcutaneous Electrical
Nerve Stimulation, Repetitive Transcranial Magnetic Stimulation
and Other Technologies for the Years 2012, 2020 & 2027

Table 76: Europe Current & Future Analysis for Neuromodulation
by Application - Chronic Pain, Failed Back Syndrome,
Depression, Epilepsy, Parkinson`s Disease, Migraine and Other
Applications - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 77: Europe Historic Review for Neuromodulation by
Application - Chronic Pain, Failed Back Syndrome, Depression,
Epilepsy, Parkinson`s Disease, Migraine and Other Applications
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR

Table 78: Europe 15-Year Perspective for Neuromodulation by
Application - Percentage Breakdown of Value Sales for Chronic
Pain, Failed Back Syndrome, Depression, Epilepsy, Parkinson`s
Disease, Migraine and Other Applications for the Years 2012,
2020 & 2027

FRANCE
Table 79: France Current & Future Analysis for Neuromodulation
by Technology - Spinal Cord Stimulation, Deep Brain
Stimulation, Sacral Nerve Stimulation, Vagus Nerve Stimulation,
Transcutaneous Electrical Nerve Stimulation, Repetitive
Transcranial Magnetic Stimulation and Other Technologies -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 80: France Historic Review for Neuromodulation by
Technology - Spinal Cord Stimulation, Deep Brain Stimulation,
Sacral Nerve Stimulation, Vagus Nerve Stimulation,
Transcutaneous Electrical Nerve Stimulation, Repetitive
Transcranial Magnetic Stimulation and Other Technologies
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR

Table 81: France 15-Year Perspective for Neuromodulation by
Technology - Percentage Breakdown of Value Sales for Spinal
Cord Stimulation, Deep Brain Stimulation, Sacral Nerve
Stimulation, Vagus Nerve Stimulation, Transcutaneous Electrical
Nerve Stimulation, Repetitive Transcranial Magnetic Stimulation
and Other Technologies for the Years 2012, 2020 & 2027

Table 82: France Current & Future Analysis for Neuromodulation
by Application - Chronic Pain, Failed Back Syndrome,
Depression, Epilepsy, Parkinson`s Disease, Migraine and Other
Applications - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 83: France Historic Review for Neuromodulation by
Application - Chronic Pain, Failed Back Syndrome, Depression,
Epilepsy, Parkinson`s Disease, Migraine and Other Applications
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR

Table 84: France 15-Year Perspective for Neuromodulation by
Application - Percentage Breakdown of Value Sales for Chronic
Pain, Failed Back Syndrome, Depression, Epilepsy, Parkinson`s
Disease, Migraine and Other Applications for the Years 2012,
2020 & 2027

GERMANY
Table 85: Germany Current & Future Analysis for Neuromodulation
by Technology - Spinal Cord Stimulation, Deep Brain
Stimulation, Sacral Nerve Stimulation, Vagus Nerve Stimulation,
Transcutaneous Electrical Nerve Stimulation, Repetitive
Transcranial Magnetic Stimulation and Other Technologies -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 86: Germany Historic Review for Neuromodulation by
Technology - Spinal Cord Stimulation, Deep Brain Stimulation,
Sacral Nerve Stimulation, Vagus Nerve Stimulation,
Transcutaneous Electrical Nerve Stimulation, Repetitive
Transcranial Magnetic Stimulation and Other Technologies
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR

Table 87: Germany 15-Year Perspective for Neuromodulation by
Technology - Percentage Breakdown of Value Sales for Spinal
Cord Stimulation, Deep Brain Stimulation, Sacral Nerve
Stimulation, Vagus Nerve Stimulation, Transcutaneous Electrical
Nerve Stimulation, Repetitive Transcranial Magnetic Stimulation
and Other Technologies for the Years 2012, 2020 & 2027

Table 88: Germany Current & Future Analysis for Neuromodulation
by Application - Chronic Pain, Failed Back Syndrome,
Depression, Epilepsy, Parkinson`s Disease, Migraine and Other
Applications - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 89: Germany Historic Review for Neuromodulation by
Application - Chronic Pain, Failed Back Syndrome, Depression,
Epilepsy, Parkinson`s Disease, Migraine and Other Applications
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR

Table 90: Germany 15-Year Perspective for Neuromodulation by
Application - Percentage Breakdown of Value Sales for Chronic
Pain, Failed Back Syndrome, Depression, Epilepsy, Parkinson`s
Disease, Migraine and Other Applications for the Years 2012,
2020 & 2027

ITALY
Table 91: Italy Cur
Read the full report: https://www.reportlinker.com/p05957502/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting